A detailed history of Rhenman & Partners Asset Management Ab transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 268,000 shares of BBIO stock, worth $7.65 Million. This represents 0.57% of its overall portfolio holdings.

Number of Shares
268,000
Previous 184,500 45.26%
Holding current value
$7.65 Million
Previous $4.67 Million 46.01%
% of portfolio
0.57%
Previous 0.46%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$23.91 - $31.3 $2 Million - $2.61 Million
83,500 Added 45.26%
268,000 $6.82 Million
Q2 2024

Aug 13, 2024

BUY
$23.0 - $31.04 $1.84 Million - $2.48 Million
80,000 Added 76.56%
184,500 $4.67 Million
Q1 2024

May 14, 2024

SELL
$27.35 - $40.45 $834,175 - $1.23 Million
-30,500 Reduced 22.59%
104,500 $3.23 Million
Q1 2023

May 11, 2023

BUY
$7.17 - $18.55 $967,950 - $2.5 Million
135,000 New
135,000 $2.24 Million

Others Institutions Holding BBIO

About BridgeBio Pharma, Inc.


  • Ticker BBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 148,246,000
  • Market Cap $4.23B
  • Description
  • BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...
More about BBIO
Track This Portfolio

Track Rhenman & Partners Asset Management Ab Portfolio

Follow Rhenman & Partners Asset Management Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.